Drugs / MesoPher
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05304208 | Nov 2021 → Dec 2025 overdue | malignant pleural mesothelioma | Erasmus Medical Center | Recruiting | No outcome recorded |
| Phase 1 | NCT05650918 | Aug 2021 → May 2023 | malignant pancreatic neoplasm | Joachim Aerts, MD PhD | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT03610360 Comparator | Jun 2018 → Jun 2022 | mesothelioma | Amphera BV | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MesoPher | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05650918 ↗ |
| Modality | Cell therapy | “autologous dendritic cells loaded with PheraLys” NCT03610360 ↗ |
| Route | Intravenous | “dendritic cells were administered intravenously” PMID 38848742 ↗ Jun 2024 |